# Investigating Retatrutide's Impact on Hormonal Levels in Postmenopausal Women

Canonical source: https://retacompare.com/research/investigating-retatrutide-s-impact-on-hormonal-levels-in-postmenopausal-women

Clinical Trials · 2024-07-26


    This study evaluates the effects of LY3437943, a form of Retatrutide, on hormonal levels in postmenopausal women. Specifically, it focuses on how this medication interacts with combined oral contraceptives in overweight or obese female participants. The research aims to assess both the pharmacological effects and the safety profile of LY3437943 during the treatment period.

 What this source covers

The study, registered under ClinicalTrials.gov (NCT06039826), investigates the effects of LY3437943 when administered subcutaneously to postmenopausal women who are overweight or obese. The primary objective is to measure the levels of ethinyl estradiol and drospirenone in the bloodstream when LY3437943 is taken alongside combined oral contraceptives. Additionally, the study will evaluate the safety and tolerability of this combination over a duration of approximately 29 weeks for each participant.

 Why it matters for Retatrutide research

Understanding the interaction between LY3437943 and hormonal contraceptives is crucial, especially given the unique metabolic profiles of postmenopausal women. This study addresses a significant gap in knowledge regarding how Retatrutide may affect hormonal balance in this demographic, which can have implications for broader therapeutic applications. The findings could inform clinicians about the safety and efficacy of Retatrutide when prescribed in conjunction with hormonal treatments.

 Key findings or claims

The study focuses on postmenopausal women who are overweight or obese.

It aims to measure the levels of ethinyl estradiol and drospirenone in the bloodstream.

Safety and tolerability of LY3437943 when used with hormonal contraceptives will be evaluated.

The study duration is approximately 29 weeks for each participant.

It investigates the pharmacological effects of LY3437943 in a specific patient population.

 Context and prior work

Retatrutide, a dual GLP-1/GIP receptor agonist, has been studied for its potential in weight management and metabolic health. Prior research has demonstrated that GLP-1 receptor agonists can influence hormonal levels and metabolic pathways, which is particularly relevant for postmenopausal women who often experience changes in body composition and hormonal balance. This study contributes to the existing literature by focusing on a specific subgroup and examining the interaction of Retatrutide with other medications, thereby enhancing the understanding of its therapeutic profile.

 Practical takeaways for researchers

Researchers should consider the implications of hormonal interactions when studying Retatrutide, especially in populations with unique metabolic challenges, such as postmenopausal women. The findings from this study may guide future research directions and clinical practices regarding the use of Retatrutide in conjunction with hormonal therapies. Furthermore, understanding the safety profile is essential for developing comprehensive treatment plans that include weight management and hormonal health.

 FAQ

 What is LY3437943?

LY3437943 is a form of Retatrutide being studied for its effects on hormonal levels in specific populations.

 How long will the study last?

The study is designed to last approximately 29 weeks for each participant.

 Why is this study important?

This study is important as it explores the safety and efficacy of Retatrutide in conjunction with hormonal contraceptives, providing insights into its use in postmenopausal women.

 Source: ClinicalTrials.gov · NCT06039826 · published 2024-07-26.

## Sources

- ClinicalTrials.gov · NCT06039826: https://clinicaltrials.gov/study/NCT06039826